The future of induction chemotherapy for head and neck squamous cell carcinoma

Oral Oncology

Volumn 48, Issue 11, 2012, Pages 1065-1067

  Haigentz Jr , Missak ^a,g   Cohen, Ezra E W ^b   Wolf, Gregory T ^c   Strojan, Primož ^d   Eisbruch, Avraham ^e   Ferlito, Alfio ^f  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d INSTITUTE OF ONCOLOGY   (Slovenia)

^e UNIVERSITY OF MICHIGAN   (United States)

^f UNIVERSITY OF UDINE   (Italy)

^g MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; HYDROXYUREA;

AIRWAY OBSTRUCTION; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CHEMORADIOTHERAPY; CHEMOSENSITIVITY; DISTANT FAILURE FREE SURVIVAL; DRUG FATALITY; DYSPHAGIA; FOLLOW UP; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPOPHARYNX CANCER; INDUCTION CHEMOTHERAPY; LARYNGECTOMY; LARYNX CANCER; LOCAL RECURRENCE FREE SURVIVAL; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NUTRITIONAL STATUS; OROPHARYNX CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTOR VARIABLE; PRIMARY TUMOR; PRIORITY JOURNAL; PROBABILITY; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RADIOSENSITIVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; REVIEW; SAMPLE SIZE; TRACHEOSTOMY; TRISMUS;

EID: 84867893188     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2012.08.009     Document Type: Editorial

References (23)

1. National Comprehensive Cancer Network (NCCN) Guidelines, Head and Neck Cancers, Version 1.2012.
2. J.B. Vermorken, E. Remenar, C. van Herpen, T. Gorlia, R. Mesia, and M. Degardin Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer N Engl J Med 357 17 2007 1695 1704
3. M.R. Posner, D.M. Hershock, C.R. Blajman, E. Mickiewicz, E. Winquist, and V. Gorbounova Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer N Engl J Med 357 17 2007 1705 1715
4. R. Hitt, J.J. Grau, A. Lopez-Pousa, A. Berrocal, C. Garcia Giron, and A. Irigoyen Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin/5-FU or docetaxel/cisplatin/5-FU follow by chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC) J Clin Oncol 27 2009 15s [suppl., abstr. 6009]
5. E.E.W. Cohen, T. Karrison, M. Kocherginsky, C.H. Huang, M. Agulnik, and B.B. Mittal DeCIDE: a phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN) J Clin Oncol 2012 30 [suppl., abstr. 5500]
6. R.I. Haddad, G. Rabinowits, R.B. Tishler, D. Adkins, F.R. Khuri, and J. Clark The PARADIGM trial: a phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LANHC) J Clin Oncol 2012 30 [suppl., abstr. 5501]
7. J.K. Salama, K.M. Stenson, E.O. Kistner, B.B. Mittal, A. Argiris, and M.E. Witt Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels Ann Oncol 19 10 2008 1787 1794
8. The Department of Veterans Affairs Laryngeal Cancer Study Group Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer N Engl J Med 324 24 1991 1685 1690
9. J.L. Lefebvre, D. Chevalier, B. Luboinski, A. Kirkpatrick, L. Collette, and T. Sahmoud Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group J Natl Cancer Inst 88 13 1996 890 899
10. A.A. Forastiere, H. Goepfert, M. Maor, T.F. Pajak, R. Weber, and W. Morrison Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer N Engl J Med 349 22 2003 2091 2098
11. J.L. Lefebvre, F. Rolland, M. Tesselaar, E. Bardet, C.R. Leemans, and L. Geoffrois Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy J Natl Cancer Inst 101 3 2009 142 152
12. Y. Pointreau, P. Garaud, S. Chapet, C. Sire, C. Tuchais, and J. Tortochaux Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation J Natl Cancer Inst 101 7 2009 498 506
13. J. Lefebvre, Y. Pointreau, F. Rolland, M. Alfonsi, A. Baudoux, and C. Sire Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): preliminary results of the randomized phase II TREMPLIN study J Clin Oncol 27 2009 15s [suppl., abstr. 6010]
14. S. Urba, G. Wolf, A. Eisbruch, F. Worden, J. Lee, and C. Bradford Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm J Clin Oncol 24 4 2006 593 598
15. F.P. Worden, J. Moyer, J.S. Lee, J.M. Taylor, S.G. Urba, and A. Eisbruch Chemoselection as a strategy for organ preservation in patients with T4 laryngeal squamous cell carcinoma with cartilage invasion Laryngoscope 119 8 2009 1510 1517
16. C. Fakhry, W.H. Westra, S. Li, A. Cmelak, J.A. Ridge, and H. Pinto Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial J Natl Cancer Inst 100 4 2008 261 269
17. F.C. Holsinger, M.S. Kies, E.M. Diaz Jr., A.M. Gillenwater, J.S. Lewin, and L.E. Ginsberg Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer J Clin Oncol 27 12 2009 1976 1982
18. V. Divi, F. Worden, M.E. Prince, A. Eisbruch, J.S. Lee, and C.R. Bradford Chemotherapy alone for organ preservation in advanced laryngeal cancer Head Neck 32 8 2010 1040 1047
19. C. Klug, D. Keszthelyi, O. Ploder, I. Sulzbacher, M. Voracek, and A. Wagner Neoadjuvant radiochemotherapy of oral cavity and oropharyngeal cancer: evaluation of tumor response by CT differs from histopathologic response assessment in a significant fraction of patients Head Neck 26 3 2004 224 231
20. J.D. Murphy, K.M. Chisholm, M.E. Daly, E.A. Wiegner, D. Truong, and A. Iagaru Correlation between metabolic tumor volume and pathologic tumor volume in squamous cell carcinoma of the oral cavity Radiother Oncol 101 3 2011 356 361
21. K.W. Mouw, A.A. Solanki, K.M. Stenson, M.E. Witt, E.A. Blair, and E.E. Cohen Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy Oral Oncol 1 May 21 2012 [Epub ahead of print]
22. M. Haigentz Jr, J. Corry, P. Strojan, and A. Ferlito Easing acceleration of head and neck chemoradiotherapy Lancet Oncol 13 2 2012 113 115
23. J.J. Beitler, and J.S. Cooper Seduction by induction? J Clin Oncol 27 1 2009 9 10